Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab+ axitinib vs. ipilimumab+ nivolumab

NJ Shah, SD Sura, R Shinde, J Shi, P Singhal… - … Oncology: Seminars and …, 2023 - Elsevier
Abstract Background Immune-Oncology (IO) therapies have changed first-line (1L) treatment
paradigm for metastatic renal cell carcinoma (mRCC) in last few years with robust clinical …
被引用次数：3 相关文章

Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab+ axitinib vs. ipilimumab+ nivolumab.

NJ Shah, SD Sura, R Shinde, J Shi, P Singhal… - Urologic …, 2023 - europepmc.org
Background Immune-Oncology (IO) therapies have changed first-line (1L) treatment
paradigm for metastatic renal cell carcinoma (mRCC) in last few years with robust clinical …

Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab+ axitinib vs. ipilimumab+ nivolumab

NJ Shah, SD Sura, R Shinde, J Shi… - Urologic …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Immune-Oncology (IO) therapies have changed first-line (1L) treatment
paradigm for metastatic renal cell carcinoma (mRCC) in last few years with robust clinical …